Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT04648137

Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls — OxyMA  

Diabetes Insipidus Clinical Trial

Official title:
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls

Clinical Trial Summary

This study is to evaluate oxytocin levels in response to MDMA administration as compared to placebo in patients with diabetes insipidus and healthy volunteers.

Clinical Trial Description

Disruption of the hypothalamic-pituitary axis due to congenital abnormalities, tumors or head trauma may cause anterior and/or posterior pituitary deficiency also known as partial or panhypopituitarism. Patients with hypopituitarism, especially those with panhypopituitarism (i.e., anterior and posterior insufficiency) often report residual symptoms and lower quality of life despite adequate substitution treatment of deficient pituitary hormones. A recent study identified a potential oxytocin deficient state in men with combined anterior and posterior deficiency. Due to the close proximity of vasopressin and oxytocin, disruption of the vasopressin system leading to diabetes insipidus could as well disturb the oxytocin system leading to low oxytocin levels. It is therefore possible that the increased psychopathology and reduced quality of life as observed in patients with central diabetes insipidus is caused by an oxytocin deficiency. Several studies documented marked acute increases in circulating oxytocin levels in response to 3,4-methylenedioxymethamphetamine (MDMA) administration as compared to placebo in healthy volunteers. MDMA could therefore be useful as a provocation test to detect an oxytocin deficiency in patients with central diabetes insipidus. This study is to investigate if oxytocin provocation following a single dose administration of MDMA is reduced in patients with central diabetes insipidus as compared to healthy volunteers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04648137
Study type Interventional
Source University Hospital, Basel, Switzerland
Contact
Status Completed
Phase N/A
Start date February 5, 2021
Completion date April 11, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT03572166 - Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study N/A
Completed NCT04550520 - Copeptin After a Subcutaneous Stimulation With Glucagon in Adults N/A
Terminated NCT02460354 - Metformin and Congenital Nephrogenic Diabetes Insipidus Phase 1
Completed NCT02523001 - Effect of Statin Treatment on Urinary AQP2 (uAQP2/01) N/A
Active, not recruiting NCT04351945 - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Completed NCT00757276 - Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study N/A
Completed NCT01940614 - Use of Copeptin in Diabetes Insipidus
Recruiting NCT02841553 - Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Active, not recruiting NCT00004364 - Study of Novel Types of Familial Diabetes Insipidus N/A
Completed NCT00004363 - Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus N/A
Completed NCT02132676 - Shared Health Appointments and Reciprocal Enhanced Support
Completed NCT02455414 - Tracking Neurodegeneration in Early Wolfram Syndrome